Objective: In cases of nonvisualization of the fetal gallbladder (NVFGB), we investigated whether amniotic fluid levels of γ-glutamyl transpeptidase (GGTP) can distinguish normal development or benign gallbladder agenesis from severe anomaly such as biliary atresia. Methods: This is a retrospective cohort study of pregnancies in which the gallbladder was not visualized in the second-trimester fetal anatomy scan. Levels of GGTP in amniotic fluid were analyzed prior to 22 weeks of gestation by amniocentesis. Data were collected regarding other fetal malformations, fetal karyotype, and screening results for cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations. Results: Of 32 cases of NVFGB, 27 (84%) had normal GGTP levels and a normal CFTR gene screening, and 1 of them had an abnormal karyotype. Three of the 5 cases with low GGTP were diagnosed with extrahepatic biliary atresia, proven by histopathological examination following termination of pregnancy. The fourth case had hepatic vasculature abnormality and the fifth isolated gallbladder agenesis. In 22 of 32 cases (68.7%), the gallbladder was detected either later in pregnancy or after delivery. Conclusion: The findings support low levels of GGTP in amniotic fluid, combined with NVFGB, as a sign of severe disease, mainly biliary atresia. Normal GGTP levels, concomitant with isolated NVFGB, carry a good prognosis.

Blazer S, Zimmer EZ, Bronshtein M: Nonvisualization of the fetal gallbladder in early pregnancy: comparison with clinical outcome. Radiology 2002;224:379-382.
Bronshtein M, Weiner Z, Abramovici H, Filmar S, Erlik Y, Blumenfeld Z: Prenatal diagnosis of gall bladder anomalies - report of 17 cases. Prenat Diagn 1993;13:851-861.
Hertzberg BS, Kliewer MA, Maynor C, McNally PJ, Bowie JD, Kay HH, Hage ML, Livingston E: Nonvisualization of the fetal gallbladder: frequency and prognostic importance. Radiology 1996;199:679-682.
Chan L, Rao BK, Jiang Y, Endicott B, Wapner RJ, Reece EA: Fetal gallbladder growth and development during gestation. J Ultrasound Med 1995;14:421-425.
Goldstein I, Tamir A, Weisman A, Jakobi P, Copel JA: Growth of the fetal gall bladder in normal pregnancies. Ultrasound Obstet Gynecol 1994;4:289-293.
Dreux S, Boughanim M, Lepinard C, Guichet A, Rival JM, de Becdelievre A, Dugueperoux I, Muller F: Relationship of non-visualization of the fetal gallbladder and amniotic fluid digestive enzymes analysis to outcome. Prenat Diagn 2012;32:423-426.
Shen O, Rabinowitz R, Yagel S, Gal M: Absent gallbladder on fetal ultrasound: prenatal findings and postnatal outcome. Ultrasound Obstet Gynecol 2011;37:673-677.
Bennion RS, Thompson JE Jr, Tompkins RK: Agenesis of the gallbladder without extrahepatic biliary atresia. Arch Surg 1988;123:1257-1260.
Davenport M: Biliary atresia: clinical aspects. Semin Pediatr Surg 2012;21:175-184.
Hinds R, Davenport M, Mieli-Vergani G, Hadzić N: Antenatal presentation of biliary atresia. J Pediatr 2004;144:43-46.
Duguépéroux I, Scotet V, Audrézet MP, Saliou AH, Collet M, Blayau M, Schmitt S, Kitzis A, Fresquet F, Müller F, Férec C: Nonvisualization of fetal gallbladder increases the risk of cystic fibrosis. Prenat Diagn 2012;32:21-28.
Ochshorn Y, Rosner G, Barel D, Bronshtein M, Muller F, Yaron Y: Clinical evaluation of isolated nonvisualized fetal gallbladder. Prenat Diagn 2007;27:699-703.
Muller F, Dommergues M, Ville Y, Lewin F, Delvalez-Morichon N, Nihoul-Fekete C, Bargy F, Dumez Y, Boue A: Amniotic fluid digestive enzymes: diagnostic value in fetal gastrointestinal obstructions. Prenat Diagn 1994;14:973-979.
Burc L, Guibourdenche J, Luton D, Noël M, Beaudeux JL, De Lagausie P, Oury JF, Porquet D: Establishment of reference values of five amniotic fluid enzymes. Analytical performances of the Hitachi 911. Application to complicated pregnancies. Clin Biochem 2001;34:317-322.
Bardin R, Danon D, Tor R, Mashiach R, Vardimon D, Meizner I: Reference values for γ-glutamyl-transferase in amniotic fluid in normal pregnancies Prenat Diagn 2009;29:703-706.
Muller F, Oury JF, Dumez Y, Boue J, Boue A: Microvillar enzyme assays in amniotic fluid and fetal tissues at different stages of development. Prenat Diagn 1988;8:189-198.
Ben-Ami M, Perlitz Y, Shalev S, Shajrawi I, Muller F: Prenatal diagnosis of extrahepatic biliary duct atresia. Prenat Diagn 2002;22:583-585.
Chalouhi GE, Muller F, Dreux S, Ville Y, Chardot C: Prenatal non-visualization of fetal gallbladder: beware of biliary atresia! Ultrasound Obstet Gynecol 2011;38:237-238, author reply 238-240.
Shen O, Rabinowitz R, Yagel S, Gal M: Comment on ‘Relationship of nonvisualization of the fetal gallbladder and amniotic fluid digestive enzymes analysis to outcome'. Prenat Diagn 2012;32:1119-1120, author reply 1121.
Serinet MO, Wildhaber BE, Broúe P, Lachaux A, Sarles J, Jacquemin E, Gauthier F, Chardot C: Impact of age at Kasai operation on its results in late childhood and adolescence: a rational basis for biliary atresia screening. Pediatrics 2009;123:1280-1286.
Brugger PC, Weber M, Prayer D: Magnetic resonance imaging of the fetal gallbladder and bile. Eur Radiol 2010;20:2862-2869.
Boughanim M, Benachi A, Dreux S, Delahaye S, Muller F: Nonvisualization of the fetal gallbladder by second-trimester ultrasound scan: strategy of clinical management based on four examples. Prenat Diagn 2008;28:46-48.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.